Intelligent MoS<sub>2</sub>-CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33253965.
- Also identified by DOI 10.1016/j.biomaterials.2020.120545.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rational design of biocompatible nanoplatforms simultaneously realizing multimodal imaging and therapeutic functions is meaningful to cancer treatment. Herein, the MoS<sub>2</sub>-CuO heteronanocomposites are designed by integrating semiconductor CuO and flower-like MoS<sub>2</sub> via a two-step hydrothermal method. After loading bovine serum albumin (BSA) and immunoadjuvant imiquimod (R837), the obtained MoS<sub>2</sub>-CuO@BSA/R837 (MCBR) nanoplatforms realize the excellent computed tomography/infrared thermal/magnetic resonance multi-mode bioimaging as well as significantly enhanced antitumor efficacy of synergetic photothermal therapy (PTT)/chemodynamic therapy (CDT)/immunotherapy. In this nanoplatform, the semiconductor CuO exhibits peroxidase-like activity, which can react with over-expressed H<sub>2</sub>O<sub>2</sub> in tumor microenvironment (TME) to generate OH for CDT via Haber-Weiss and Fenton-like reactions. And this process can be further accelerated by the generated heat of MoS<sub>2</sub> under 808 nm laser irradiation. More importantly, the obtained multifunctional MCBR nanoplatforms under near-infrared (NIR) irradiation would destroy tumor cells to generate tumor associated antigens (TAAs), which combine with R837 as an adjuvant to trigger strong antitumor immune responses for effectively eliminating primary tumors and metastatic tumors.
Medical subject headings
- Molybdenum
- Photothermal Therapy